Cargando…
The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604569/ https://www.ncbi.nlm.nih.gov/pubmed/36294532 http://dx.doi.org/10.3390/jcm11206210 |
_version_ | 1784817846978609152 |
---|---|
author | Huang, Wei-Chang Lin, Sheng-Hao Hang, Liang-Wen Lin, Ching-Hsiung Hsu, Jeng-Yuan |
author_facet | Huang, Wei-Chang Lin, Sheng-Hao Hang, Liang-Wen Lin, Ching-Hsiung Hsu, Jeng-Yuan |
author_sort | Huang, Wei-Chang |
collection | PubMed |
description | Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-related quality of life and its safety in patients with COPD in a routine clinical care setting. This multi-center, prospective, six-month observational study recruited patients diagnosed with COPD and treated with GLY at three medical centers in central Taiwan. The full analysis set (n = 102) had a significant improvement in the Clinical COPD Questionnaire total (mean ± SD = −0.39 ± 0.90, p = 0.002), symptoms (mean ± SD = −0.61 ± 0.90, p < 0.001) and mental state scores (mean ± SD = −0.54 ± 1.72, p = 0.021) but not the functional state score (mean ± SD = −0.10 ± 1.15, p = 0.529). During the observational period, 58 patients (52.73%) experienced adverse events; only one adverse event (dizziness) was suspected to be related to the study drug. Three patients (2.73%) discontinued the study and GLY treatment because of an adverse event. One patient (0.91%) died during the study period because of a cerebral infarction, which was judged to be not associated with GLY treatment. In conclusion, GLY could be effective in improving the health status and is safe for patients with COPD in a real-life setting. |
format | Online Article Text |
id | pubmed-9604569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96045692022-10-27 The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan Huang, Wei-Chang Lin, Sheng-Hao Hang, Liang-Wen Lin, Ching-Hsiung Hsu, Jeng-Yuan J Clin Med Article Glycopyrronium (GLY) is a pharmacological maintenance treatment for chronic obstructive pulmonary disease (COPD). However, its effectiveness and tolerability for COPD patients in routine clinical practice have not been well-investigated. This study aimed to assess the effectiveness of GLY on health-related quality of life and its safety in patients with COPD in a routine clinical care setting. This multi-center, prospective, six-month observational study recruited patients diagnosed with COPD and treated with GLY at three medical centers in central Taiwan. The full analysis set (n = 102) had a significant improvement in the Clinical COPD Questionnaire total (mean ± SD = −0.39 ± 0.90, p = 0.002), symptoms (mean ± SD = −0.61 ± 0.90, p < 0.001) and mental state scores (mean ± SD = −0.54 ± 1.72, p = 0.021) but not the functional state score (mean ± SD = −0.10 ± 1.15, p = 0.529). During the observational period, 58 patients (52.73%) experienced adverse events; only one adverse event (dizziness) was suspected to be related to the study drug. Three patients (2.73%) discontinued the study and GLY treatment because of an adverse event. One patient (0.91%) died during the study period because of a cerebral infarction, which was judged to be not associated with GLY treatment. In conclusion, GLY could be effective in improving the health status and is safe for patients with COPD in a real-life setting. MDPI 2022-10-21 /pmc/articles/PMC9604569/ /pubmed/36294532 http://dx.doi.org/10.3390/jcm11206210 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Wei-Chang Lin, Sheng-Hao Hang, Liang-Wen Lin, Ching-Hsiung Hsu, Jeng-Yuan The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title | The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title_full | The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title_fullStr | The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title_full_unstemmed | The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title_short | The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan |
title_sort | effectiveness and tolerability of glycopyrronium for patients with chronic obstructive pulmonary disease in a clinical setting: glare-taiwan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604569/ https://www.ncbi.nlm.nih.gov/pubmed/36294532 http://dx.doi.org/10.3390/jcm11206210 |
work_keys_str_mv | AT huangweichang theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT linshenghao theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT hangliangwen theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT linchinghsiung theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT hsujengyuan theeffectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT huangweichang effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT linshenghao effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT hangliangwen effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT linchinghsiung effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan AT hsujengyuan effectivenessandtolerabilityofglycopyrroniumforpatientswithchronicobstructivepulmonarydiseaseinaclinicalsettingglaretaiwan |